Saturday 17 October 2026
Export OMDA’s income statement to Excel — free account
Omada Health, Inc.
OMDA Healthcare Health Information Services
Omada Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $260.2 million, up 53.2% from fiscal 2024. In the quarter to June 2026, revenue grew 43.1%, EPS grew 137.5% and free cash flow grew 45.7%, each against the same quarter a year earlier.
17.63
1.04
−5.57%
Follow OMDA
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
2.22 | 0.00 | 0.00 |
Altman Z-Score |
3.98 | — | — |
Altman Z″-Score (non-manufacturers) |
2.28 | (9.72) | — |
P/FCF ratio |
46.55 | 0.00 | 0.00 |
Beneish M-Score |
(2.59) | — | — |
P/Operating CF |
27.04 | (11.76) | (11.76) |
P/B ratio |
2.52 | 0.00 | 0.00 |
Price to Tangible BV |
2.70 | 0.00 | 0.00 |
EV/Sales |
1.48 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
21.15 | (2.84) | (2.84) |
EV/FCF |
31.09 | (2.58) | (2.58) |
Quick Ratio |
3.39 | 1.85 | — |
Current Ratio |
3.60 | 2.10 | — |
Net Debt/EBITDA |
77.72 | 1.30 | 0.00 |
Debt/Assets |
0.00% | 19.73% | 0.00% |
Debt/Equity |
0.00 | (0.08) | 0.00 |
Asset Turnover |
1.14 | 2.25 | 0.00 |
Operating CF/Net income |
(1.43) | 0.73 | 0.74 |
Capex/Depreciation |
(0.64) | (0.49) | (0.44) |
Interest Coverage |
(4.72) | (9.69) | (14.03) |
| 16.52% | 0.00% | 0.00% | |
| (5.60%) | (62.48%) | 0.00% | |
ROIC |
(97.89%) | 0.00% | 0.00% |
Return on Tangible Assets |
(6.23%) | (72.82%) | 0.00% |
Average Days of Receivables |
48.51 | 50.34 | 0.00 |
Research and Development Expense of Revenue |
15.63% | 21.16% | 27.48% |
Selling, General and Administrative Expense of Revenue |
54.66% | 65.14% | 83.26% |
Intangible Assets out of Total Assets |
0.05 | 0.12 | 0.00 |
Share Based Compensation of Revenue |
4.98% | 5.55% | 7.12% |
Graham Net Nets |
0.34 | (2.23) | (2.23) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(8.60%) | (21.69%) | (21.69%) |
Free Cash Flow Yield |
2.15% | (29.23%) | (29.23%) |
Revenue per Share |
7.10 | 21.99 | 17.32 |
Operating CF per Share |
0.50 | (4.43) | (7.01) |
Capex per Share |
(0.16) | (0.50) | (0.41) |
Free Cash Flow per Share |
0.34 | (4.93) | (7.43) |
Cash per Share |
6.06 | 9.89 | 0.00 |
Shareholders Equity per Share |
6.27 | (49.79) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
6.27 | (49.79) | 0.00 |
Free Cash Flow |
12.42 | (38.04) | (52.66) |
Working Capital |
197.21 | 59.11 | — |
Capital Expenditures |
(5.83) | (3.86) | (2.92) |
Net Current Asset Value |
197.21 | (422.24) | 0.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
1.15 | 1.39 | 0.00 |
Cash ROIC |
2.75% | 13.67% | 0.00% |
Accounts Receivable Turnover |
8.97 | 0.00 | 0.00 |
Accounts Payable Turnover |
12.36 | 0.00 | 0.00 |
Inventory Turnover |
22.94 | 0.00 | 0.00 |
Average Days of Payables |
42.02 | 22.73 | 0.00 |
Days of Inventory on Hand |
18.34 | 17.98 | 0.00 |
Average Receivables |
29.00 | — | — |
Average Payables |
7.22 | — | — |
Average Inventory |
3.89 | — | — |
Average Assets |
228.15 | 75.45 | — |
Average Common Equity |
(77.36) | — | — |
Columns are period end dates